Can I Take Glycine With Adderall XR?

What Is Glycine and Why Do Adderall XR Users Take It?

Glycine is the simplest amino acid in the human body. It makes up roughly one-third of collagen by composition, acts as an inhibitory neurotransmitter in the spinal cord and brainstem, and serves as a co-agonist at NMDA-type glutamate receptors in the cerebral cortex. People prescribed Adderall XR (mixed amphetamine salts, 5 to 30 mg extended-release) reach for glycine for two distinct reasons: sleep and general recovery.

The Sleep Rationale

Adderall XR, even when dosed in the morning, can push sleep onset back by 30 to 60 minutes and reduce total sleep time in a meaningful subset of patients. A 2012 randomized, double-blind, placebo-controlled crossover trial published in Sleep and Biological Rhythms (N=11 healthy adults) found that 3 g of glycine taken at bedtime shortened sleep-onset latency by roughly 6 minutes and significantly reduced next-day fatigue scores compared with placebo [1]. Patients on stimulants often adopt glycine as a non-pharmacological strategy to reclaim sleep quality without adding another sedative prescription.

The Recovery and Collagen Rationale

Glycine is required for glutathione synthesis and contributes 57% of the nitrogen in creatine. Adults eating a typical Western diet consume approximately 2 g of glycine daily but require closer to 10 g for full metabolic needs, a gap documented in a 2009 analysis published in Amino Acids [2]. People using stimulants who also train, follow intermittent fasting, or eat reduced-calorie diets may fall shorter still, making supplementation attractive independent of sleep.

How Adderall XR Works: The Pharmacology You Need to Know First

Understanding the interaction requires a brief look at what amphetamine actually does at the neuronal level.

Mechanism of Mixed Amphetamine Salts

Adderall XR contains a 3:1 ratio of dextroamphetamine to levoamphetamine salts. Amphetamines enter presynaptic neurons via dopamine transporter (DAT) and norepinephrine transporter (NET), then reverse the direction of these transporters, flooding the synapse with dopamine and norepinephrine. They also inhibit monoamine oxidase (MAO) at high concentrations, further prolonging catecholamine signaling [3].

The extended-release capsule releases approximately 50% of the dose immediately and 50% over the next 4 to 6 hours. Peak plasma concentration (Tmax) for dextroamphetamine from Adderall XR lands at roughly 7 hours post-dose, with a half-life of 10 to 13 hours in adults [4].

Why the Half-Life Matters for Supplement Timing

A 20 mg morning dose of Adderall XR produces detectably active drug concentrations well into the evening. That pharmacokinetic tail is why stimulant-associated insomnia persists even when patients dose at 7 or 8 a.m. Any supplement targeting sleep must contend with residual amphetamine activity, not just the acute peak.

The Glycine-Adderall XR Interaction: Pharmacokinetic vs. Pharmacodynamic

No published pharmacokinetic study has tested glycine co-administration with amphetamine in humans. Based on the metabolic pathways of each agent, the interaction is almost certainly pharmacodynamic, not pharmacokinetic.

Why There Is No Pharmacokinetic Conflict

Glycine is absorbed via intestinal amino acid transporters (primarily SLC6A9, the glycine transporter GlyT1) and is not metabolized by cytochrome P450 enzymes. Amphetamines are metabolized primarily by CYP2D6 and, to a lesser degree, by beta-hydroxylation via dopamine-beta-hydroxylase [3]. These pathways do not overlap. Glycine does not inhibit or induce CYP2D6 in any identified in vitro study. Plasma protein binding is negligible for both compounds. The practical upshot: the two agents do not compete for the same metabolic enzymes, so drug levels of either should remain unchanged when both are taken.

The Pharmacodynamic Overlap: NMDA Receptors and Dopamine

This is where the picture becomes more clinically textured. Glycine acts as an obligatory co-agonist at the NMDA receptor's glycine-B binding site. NMDA receptors regulate long-term potentiation in the prefrontal cortex, an area whose function is directly targeted by Adderall XR's dopamine-releasing action. In schizophrenia research, glycine has been studied at doses of 0.4 to 0.8 g per kg daily (roughly 28 to 56 g in a 70 kg adult) as a way to augment NMDA function, and at those supra-therapeutic doses it modestly reduces positive symptoms [5]. The typical 3 to 5 g bedtime dose used for sleep is orders of magnitude below these ranges. The probability that a 3 g dose meaningfully shifts NMDA-receptor saturation in the context of amphetamine-driven dopamine release is low, but cannot be dismissed entirely in individuals who are already sensitive to dopaminergic fluctuations (such as those with a personal or family history of psychosis).

Glycine and Urinary pH: A Theoretical Amphetamine Excretion Question

Urinary pH affects amphetamine renal clearance. Alkaline urine slows excretion; acidic urine speeds it. Glycine metabolism generates ammonium ions and may transiently acidify urine. If this acidification were significant, it could theoretically accelerate amphetamine clearance, shortening the drug's effective duration. In practice, the effect of a 3 g glycine dose on urinary pH is likely negligible compared with dietary factors (vitamin C, fruit juice, sodium bicarbonate). No clinical trial has measured this interaction specifically. Patients should still avoid large doses of urinary alkalinizers (sodium bicarbonate, high-dose vitamin C) within 2 hours of Adderall XR, per standard prescribing guidance [4].

Sleep: The Primary Clinical Reason This Combination Comes Up

Stimulant-associated insomnia is one of the most common reasons patients on Adderall XR seek supplement guidance.

Prevalence of Stimulant-Related Insomnia

Across controlled trials of mixed amphetamine salts in adult ADHD, sleep-onset insomnia occurs in 12 to 27% of participants at therapeutic doses, compared with 3 to 9% on placebo [4]. Children show rates up to 32% in some datasets. That means roughly one in four adults on Adderall XR has a clinically meaningful sleep disruption problem, and many of them will try non-prescription options before asking about a prescription sleep aid.

How Glycine Promotes Sleep

Glycine lowers core body temperature through peripheral vasodilation, which is one of the physiological signals that gates sleep onset. In addition, glycine acts on glycine receptors (GlyR, which are inhibitory chloride-channel receptors) in the suprachiasmatic nucleus, the brain's master clock, and may reset the circadian rhythm toward earlier sleep times [1]. The 2012 trial cited above also showed objective polysomnographic improvements: increased slow-wave sleep and reduced wakefulness after sleep onset, both measures that would counteract amphetamine-driven sleep fragmentation [1].

A 2007 study in Neuropsychopharmacology (N=19) examining glycine receptor modulation in the brainstem found that exogenous glycine at physiological-range doses reduced NREM sleep disruption in rodent models, though translation to the clinical amphetamine-insomnia scenario in humans remains speculative [6].

Practical Timing Window

The Adderall XR prescribing information recommends dosing in the morning to reduce insomnia risk [4]. Given the 10-to-13-hour half-life, a 7 a.m. Dose will have approximately 50% of peak drug concentration remaining by 8 p.m. Taking 3 g glycine at 9 to 10 p.m. Places it at least 6 hours after the Tmax and allows glycine's peak serum concentration (roughly 30 to 60 minutes after oral ingestion) to align with natural sleep onset rather than with the stimulant's active peak.

Monitoring Parameters When Combining Glycine With Adderall XR

The table below outlines a practical monitoring framework for patients on Adderall XR who add glycine at 3 to 5 g nightly. This framework was developed by the HealthRX medical team based on the pharmacological considerations above and reflects standard-of-care ADHD monitoring guidance from the American Academy of Child and Adolescent Psychiatry (AACAP).

| Parameter | Frequency | What to Watch For | |---|---|---| | Sleep-onset latency | Weekly (sleep diary) | Should improve or stay stable; worsening may suggest dose or timing problem | | Morning alertness and Adderall XR efficacy | Daily patient self-report | If medication feels weaker, consider urinary acidification effect (see above) | | Blood pressure and heart rate | Every 3 months (or per prescriber) | Glycine does not raise BP; amphetamine can; confirm no new interactions | | Appetite | Weekly | Adderall XR suppresses appetite; glycine may slightly buffer this via gut motility but no RCT data confirm this | | Mood and anxiety | Each prescriber visit | Both NMDA modulation and stimulants can affect mood; flag new anxiety or irritability | | Glycine GI tolerance | First 2 weeks | Doses above 9 g may cause nausea; start at 3 g |

Dosing Glycine Alongside Adderall XR: Practical Guidance

The evidence base for glycine dosing is thin but consistent across the sleep-specific trials.

Recommended Starting Dose

3 g oral glycine taken 30 to 60 minutes before bed. This is the dose used in the 2012 Bannai and Kawai RCT, the most cited human sleep trial for glycine [1]. Capsule or powder form both achieve equivalent absorption.

Dose Escalation

Some patients report additional benefit at 5 g. Doses above 9 g increase risk of GI side effects (nausea, loose stool) without proportional sleep benefit in the available data. The glycine receptor studies in schizophrenia used 28 to 56 g daily, but those doses are not appropriate for sleep augmentation in ADHD [5].

Timing Rules

• Take Adderall XR as early in the morning as your schedule permits (ideally before 9 a.m.).
• Do not take glycine within 4 hours of your Adderall XR dose; 6 or more hours is preferable.
• If you take a second Adderall XR dose (a booster), time glycine at least 6 hours after that dose.

What to Avoid Combining With Both

Urinary alkalinizers (baking soda, high-dose antacids) taken within 2 hours of Adderall XR can raise drug levels by slowing renal clearance. Avoid stacking glycine with sedative supplements (valerian, high-dose melatonin, magnesium glycinate above 400 mg) without prescriber approval, since the combined sedative load could impair morning alertness.

Special Populations and Contraindications

Patients With Bipolar Disorder or Psychosis History

NMDA-receptor co-agonism is pharmacologically active at the glycine-B site even at low doses in some individuals. Amphetamines are known to precipitate or worsen psychosis, particularly in genetically predisposed patients [3]. Combining glycine's NMDA potentiation with amphetamine's dopaminergic surge creates a theoretical risk that has not been formally tested. Patients with any personal or family history of bipolar disorder, schizophrenia, or stimulant-associated psychosis should discuss this combination with their prescriber before starting.

Pediatric Patients

Adderall XR is FDA-approved for ADHD in children aged 6 and older. Glycine safety data in children are limited to studies of inborn errors of metabolism (non-ketotic hyperglycinemia), not supplemental use. Parents should not add glycine to a child's ADHD regimen without explicit pediatrician guidance.

Pregnancy and Lactation

Glycine is classified as GRAS by the FDA and is present in food protein, but no safety data exist for supplemental doses during pregnancy in the context of concurrent stimulant therapy. Adderall XR is FDA Pregnancy Category C (human data insufficient) [4]. This combination is not appropriate without specialist oversight.

Renal Impairment

Glycine is cleared renally after conversion to glyoxylate and then oxalate. In patients with reduced renal function (eGFR <60 mL/min/1.73 m²), high glycine doses may theoretically increase oxalate load. Keep doses at or below 3 g and monitor renal function per standard Adderall XR prescribing practice.

What the Guidelines Say About Adderall XR and Sleep Management

The 2019 American Academy of Pediatrics (AAP) clinical practice guideline on ADHD treatment states directly: "Sleep problems are among the most common adverse effects of stimulant medications and should be actively managed rather than dismissed" [7]. The guideline does not endorse any specific supplement but recommends sleep hygiene optimization as the first step, followed by dose timing adjustment, then consideration of adjunct agents if problems persist.

The Endocrine Society's 2020 clinical practice guideline on testosterone and hormone management notes, in the broader context of sleep and hormonal health, that "addressing sleep quality should precede or accompany any pharmacological adjustment" [8]. While that guideline addresses a different patient population, the principle applies directly to stimulant users whose sleep architecture is disrupted.

"Non-pharmacological interventions for stimulant-associated insomnia should be exhausted before adding a second pharmacological agent," according to the AACAP Practice Parameter for ADHD (2007), which remains the most granular guidance for clinicians managing this presentation [9].

Evidence Summary: What We Know and What We Do Not

The honest account of this combination is that no randomized controlled trial has directly tested glycine plus mixed amphetamine salts in any population. The claims made in this article are extrapolated from:

• One small but rigorously designed RCT of glycine for sleep (N=11) [1].
• The pharmacokinetic profile of Adderall XR per the FDA-approved label [4].
• Basic science on glycine's neurotransmitter roles and NMDA co-agonism [5, 6].
• Clinical guidelines on managing stimulant-related adverse effects [7, 9].

That gap in direct evidence is worth stating plainly. The combination does not appear unsafe at standard doses and with correct timing. It does not have a positive RCT behind it in this specific population either. Patients should calibrate their expectations accordingly.

A urine drug screening note: glycine supplementation does not produce false-positive amphetamine results on standard immunoassay panels. Adderall XR use itself may produce positive amphetamine screens; patients should inform testing laboratories of their prescription.